Irinotecan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) recommended or restricted irinotecan, while CIPM (Spain) and PBAC (Australia) did not recommend it.
The file has been open for more than a decade: 16 years separate the first record, 3 Sep 2008 at HAS (France), from the most recent, 26 Sep 2024 at CIPM (Spain).
No assessment is on file from SMC (Scotland), AWMSG (Wales), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for irinotecan by the agency that label one in English (PBAC).
4 of these 18 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess irinotecan, on 3 Sep 2008; CIPM (Spain) did not open a file until 26 Sep 2024 — an unusually long tail of 16 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 11 years in total.
2 of the 4 agencies here assessed irinotecan more than once, HAS (France) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed irinotecan.
The full ledger for irinotecan reads 12 recommended, 4 not recommended, 1 other and 1 advice.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 26 Sep 2024 | SECRETARIA DE ESTADO DE SANIDAD 39 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicaciones terapéuticas autorizadas: ON… | not financed by the SNS · art. 92 d, e | source |
| HAS (France) | 6 Oct 2021 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 13 May 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2018 | Indicated in the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and folinic acid (leucovorin) in adult patients who have been … | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Requir… | source |
| PHARMAC (New Zealand) | 1 Nov 2012 | Adenocarcinoma | funding application decided · decision reached | source |
13 further decisions for irinotecan, across 2 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- docetaxel — same ATC class L01C — Antineoplastics
- paclitaxel — same ATC class L01C — Antineoplastics
- topotecan — same ATC class L01C — Antineoplastics
- trabectedin — same ATC class L01C — Antineoplastics
- cabazitaxel — same ATC class L01C — Antineoplastics
- vinorelbine — same ATC class L01C — Antineoplastics
Coverage: 18 decisions for irinotecan from 4 agencies, 2008 to 2024. Data to 7 Sep 2026. ATC class L01C — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.